Neurocrine Biosciences Strengthens Leadership in Endocrinology and Rare Disease through Soleno Therapeutics Acquisition

Neurocrine Biosciences has finalized the acquisition of Soleno Therapeutics, enhancing its capacity in addressing Prader-Willi syndrome (PWS) and reinforcing its commitment to providing life-changing treatments for patients with unmet needs.